|
| 36720081 | Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1). | | 2023 |
| 36763961 | Symptoms and associated impact in pre- and postmenopausal women with sexual arousal disorder: a concept elicitation study. | | 2023 |
| 37369079 | Efficacy, tolerability, and endometrial safety of ospemifene compared with current therapies for the treatment of vulvovaginal atrophy: a systematic literature review and network meta-analysis. | | 2023 |
| 34999484 | Clinically Meaningful Benefit in Women with Hypoactive Sexual Desire Disorder Treated with Flibanserin. | Sexual Medicine | 2022 |
| 35594467 | Individual Benefits and Risks of Intravaginal Estrogen and Systemic Testosterone in the Management of Women in the Menopause, With a Discussion of Any Associated Risks for Cancer Development. | Cancer journal (Sudbury, Mass.) | 2022 |
| 36075250 | Review of menopausal hormone therapy with estradiol and progesterone versus other estrogens and progestins. | Gynecological Endocrinology | 2022 |
| 35869024 | Sexual Dysfunction as a Harbinger of Cardiovascular Disease in Postmenopausal Women: How Far Are We? | Journal of Sexual Medicine | 2022 |
| 35674644 | On no! Where did my "big O" go? Or could severe menopausal symptoms have stolen my orgasm? | Menopause | 2022 |
| 35475708 | Assessing the Burden of Illness Associated with Acquired Generalized Hypoactive Sexual Desire Disorder. | Journal of Women's Health | 2022 |
| 36400683 | Effects of Flibanserin on Subdomain Scores of the Female Sexual Function Index in Women With Hypoactive Sexual Desire Disorder. | Sexual Medicine | 2022 |
| 36529480 | Response to Commentary by Spielmans. | | 2022 |
| 35230162 | Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. | Journal of Women's Health | 2022 |
| 35147466 | Safety Profile of Bremelanotide Across the Clinical Development Program. | Journal of Women's Health | 2022 |
| 34435897 | Bone Mineral Density Changes Associated With Pregnancy, Lactation, and Medical Treatments in Premenopausal Women and Effects Later in Life. | Journal of Women's Health | 2021 |
| 33906204 | A core outcome set for vasomotor symptoms associated with menopause: the COMMA (Core Outcomes in Menopause) global initiative. | Menopause | 2021 |
| 33797277 | International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. | J Womens Health (Larchmt) | 2021 |
| 33792440 | International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. | Climacteric | 2021 |
| 34054104 | Evaluation of endometrial progesterone receptor expression after 12 weeks of exposure to a low-dose vaginal estradiol insert. | Menopause | 2021 |
| 33785318 | Segesterone acetate serum levels with a regression model of continuous use of the segesterone acetate/ethinyl estradiol contraceptive vaginal system. | | 2021 |
| 33835907 | Failure of a Meta-analysis: A Commentary on Glen Spielmans's "Re-Analyzing Phase III Bremelanotide Trials for 'Hypoactive Sexual Desire Disorder in Women'". | Journal of Sex Research | 2021 |
| 33973541 | A core outcome set for genitourinary symptoms associated with menopause: the COMMA (Core Outcomes in Menopause) global initiative. | Menopause | 2021 |
| 33814355 | International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. | J Sex Med | 2021 |
| 33259782 | Efficacy, safety, and tolerability of a levonorgestrel/ethinyl estradiol transdermal delivery system: Phase 3 clinical trial results. | | 2021 |
| 32702363 | Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids. | Am J Obstet Gynecol | 2021 |
| 34674962 | Androgen therapy for women after menopause. | | 2021 |
| 33110039 | TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial. | Menopause | 2020 |
| 31971678 | Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids. | N Engl J Med | 2020 |
| 32068684 | MsFLASH network vaginal health trial: absence of evidence is NOT evidence of absence. | Menopause | 2020 |
| 31735618 | Effects of Alcohol Administered With Flibanserin in Healthy Premenopausal Women: A Randomized, Double-Blind, Single-Dose Crossover Study. | Journal of Sexual Medicine | 2020 |
| 32063470 | Methodological Challenges in Studying Testosterone Therapies for Hypoactive Sexual Desire Disorder in Women. | J Sex Med | 2020 |
| 31663981 | Physical characteristics and properties of estradiol softgel vaginal inserts. | Menopause | 2020 |
| 31977666 | Depression, anxiety, and "the incredible shrinking vagina". | Menopause | 2020 |
| 32460605 | Female Hypoactive Sexual Desire Disorder: A Practical Guide to Causes, Clinical Diagnosis, and Treatment. | Journal of Women's Health | 2020 |
| 32459423 | Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas. | Obstet Gynecol | 2020 |
| 30707049 | Flibanserin for Premenopausal Hypoactive Sexual Desire Disorder: Pooled Analysis of Clinical Trials. | Journal of Women's Health | 2019 |
| 31599847 | Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. | Obstetrics and Gynecology | 2019 |
| 31599840 | Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. | Obstetrics and Gynecology | 2019 |
| 30489424 | Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms. | Menopause | 2019 |
| 30204639 | In Reply. | Menopause | 2019 |
| 30531443 | Women's experience of vulvovaginal symptoms associated with menopause. | Menopause | 2019 |
| 30516713 | Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms. | Menopause | 2019 |
| 31526199 | Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopause. | | 2019 |
| 31522985 | Effects of Timing of Flibanserin Administration Relative to Alcohol Intake in Healthy Premenopausal Women: A Randomized, Double-Blind, Crossover Study. | Journal of Sexual Medicine | 2019 |
| 31519497 | Safety and Tolerability of Evening Ethanol Consumption and Bedtime Administration of Flibanserin in Healthy Premenopausal Female Subjects. | Sexual Medicine | 2019 |
| 30694917 | Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial. | Menopause | 2019 |
| 31488288 | Global Consensus Position Statement on the Use of Testosterone Therapy for Women. | J Sex Med | 2019 |
| 31474158 | Global Consensus Position Statement on the Use of Testosterone Therapy for Women. | Climacteric | 2019 |
| 30862193 | TX-004HR clinically improves symptoms of vulvar and vaginal atrophy in postmenopausal women. | Climacteric | 2019 |
| 31484631 | Global Consensus Position Statement on the use of Testosterone Therapy for Women. | Maturitas | 2019 |
| 30846116 | Toward a More Evidence-Based Nosology and Nomenclature for Female Sexual Dysfunctions-Part III. | Journal of Sexual Medicine | 2019 |